Intervention not reported
Salt intake in grams per day ‐ all eligible studies that provided sufficient data for quantitative analysis of overall impact (n = 10 countries) · ‐level interventions in national government jurisdictions to reduce sodium consumption
1 finding from 1 review
Intervention not reported
Salt intake in grams per day ‐ subset of initiatives that are multi‐component and incorporate activities of a structural nature (n = 7 countries) · ‐level interventions in national government jurisdictions to reduce sodium consumption
1 finding from 1 review
Intervention not reported
Salt intake in grams per day ‐ women only (n = 9 countries) · ‐level interventions in national government jurisdictions to reduce sodium consumption
1 finding from 1 review
Intervention not reported
Salt intake in grams per day ‐ men only (n = 9 countries) · ‐level interventions in national government jurisdictions to reduce sodium consumption
1 finding from 1 review
Neonatal death (death within the first 28 days of life) · preterm prelabour rupture of membranes (PPROM)
1 finding from 1 review
Neonatal death (death within the first 28 days of life) · preterm prelabour rupture of membranes (PPROM)
It is very uncertain whether SOF Immunological sealant changes neonatal death (death within the first 28 days of life) compared with standard care (very low certainty).
1 finding from 1 review
Intervention not reported
Daily hours of hearing aid use Self‐reported or data‐logged average hours of use per day. Scale from: 0 to 12 hours · adults with hearing loss who use hearing aids
1 finding from 1 review
Intervention not reported
Daily hours of hearing aid use Average self‐reported or data‐logged hours of use per day. Scale from: 0 to 12 hours · adults with hearing loss who use hearing aids
1 finding from 1 review
Hot flush frequency (number/day) · women with hot flushes
Transdermal beta‐estradiol patch showed no clear difference in frequency of hot flushes Beta‐estradiol patch 0.0375‐0.10 mg/day compared with placebo (low certainty).
1 finding from 1 review
Change in frequency of hot flushes from baseline to end of study · women with hot flushes
Intranasal beta‐estradiol showed no clear difference in frequency of hot flushes Change from baseline Intranasal… compared with placebo (moderate certainty).
1 finding from 1 review
Adverse effects Intranasal beta‐estradiol 0.021 mg/day, 0.029 mg/day or 0.040 mg/day · women with hot flushes
Intranasal beta‐estradiol probably leads to higher adverse effects Intranasal beta‐estradiol 0.021 mg/day, 0.029 mg/day… compared with placebo (moderate certainty).
1 finding from 1 review
Hot flush frequency (number/day) · women with hot flushes
1 finding from 1 review
Adverse events Beta‐estradiol patch 0.05 or 0.1 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes
1 finding from 1 review
Frequency of hot flushes Oral beta‐estradiol 1.0 and 2.0 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes
1 finding from 1 review
Adverse events Oral beta‐estradiol 1.0 or 2.0 mg/day vs CEE 0.625 or 1.25 mg/day · women with hot flushes
1 finding from 1 review
Intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day · women with hot flushes
Transdermal beta‐estradiol patch showed no clear difference in intensity of hot flushes Beta‐estradiol patch 0.025‐0.05 mg/day compared with placebo (low certainty).
1 finding from 1 review
Adverse effects Beta‐estradiol patch dose 0.10 mg/day · women with hot flushes
Transdermal beta‐estradiol patch may leads to higher adverse effects Beta‐estradiol patch dose 0.10 mg/day compared with placebo (low certainty).
1 finding from 1 review
Hot flush frequency (number/day) · women with hot flushes
1 finding from 1 review
Adverse effects Beta‐estradiol gel dose 1.5 mg/day · women with hot flushes
1 finding from 1 review
Hot flush frequency (number/day) · women with hot flushes
Oral beta‐estradiol showed no clear difference in frequency of hot flushes Oral beta‐estradiol 0.5‐1.0 mg/day compared with placebo (low certainty).
1 finding from 1 review